Vision-Related Quality of Life Associated with Unilateral and Bilateral Ocular Conditions

被引:35
作者
Brown, Gary C. [1 ,2 ,3 ,4 ]
Brown, Melissa M. [1 ,2 ,3 ,4 ]
Stein, Joshua D. [5 ]
Smiddy, William E. [6 ]
机构
[1] Ctr Value Based Med, POB 3417, Hilton Head Isl, SC 29938 USA
[2] Jefferson Med Univ, Wills Eye Hosp, Philadelphia, PA USA
[3] Eye Res Inst, Philadelphia, PA USA
[4] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA
[5] Univ Michigan, Kellogg Eye Ctr, Sch Med, Glaucoma Serv, Ann Arbor, MI 48109 USA
[6] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA
关键词
VALUE-BASED MEDICINE; TIME TRADE-OFF; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; COST-EFFECTIVENESS; CATARACT-SURGERY; UTILITY-ASSESSMENT; VISUAL-LOSS; PHOTOCOAGULATION; RANIBIZUMAB;
D O I
10.1016/j.ophtha.2017.12.033
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To present ophthalmic patient time-tradeoff vision utilities for quantifying vision-related quality-of-life when the fellow eye still has good vision. These utilities are important for performing reliable cost-utility analyses. Design: Consecutive time-tradeoff vision utilities were obtained from ophthalmic patients with good vision (20/20-20/25) in one eye and vision ranging from 20/20 to no light perception in the fellow eye over a 15-year period from 2000 through 2014. Participants: Five hundred eighty-six ophthalmic participant interviews from Wills Eye Hospital, New York Eye and Ear Hospital, and ophthalmology office practices in Pennsylvania and New Jersey. Methods: Participants underwent a full ophthalmic examination, after which time-tradeoff vision utilities were obtained by personal interview by the authors using a standardized, validated instrument. Main Outcome Measures: Time-tradeoff vision utilities. Results: Mean time-tradeoff vision utilities were as follows in participants with good vision (20/20-20/25) in at least one eye and the following visions in the fellow eyes: no light perception, 0.79; counting fingers to light perception, 0.87; 20/200 to 20/400, 0.88; 20/60 to 20/100, 0.88; 20/30 to 20/50, 0.87; and 20/20 to 20/25, 0.94. Conclusions: In people with good vision (20/20-20/25) in one eye, the associated mean time-tradeoff vision utility is a remarkably consistent 0.87 to 0.88 when vision in the fellow eye ranges from 20/30 to light perception. Vision of 20/20 to 20/25 in the fellow eye results in a significantly higher associated utility of 0.94 (P<0.01), whereas vision of no light perception in the fellow eye results in a significantly lower utility of 0.079 (P<0.01). These utilities are important for calculating reliable patient value (quality-adjusted life-year) gains in ophthalmic cost-utility analysis populations in which there is unilateral and bilateral disease involvement. (C) 2018 by the American Academy of Ophthalmology
引用
收藏
页码:965 / 971
页数:7
相关论文
共 34 条
[1]   Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration [J].
Boyer, David S. ;
Antoszyk, Andrew N. ;
Awh, Carl C. ;
Bhisitkul, Robert B. ;
Shapiro, Howard ;
Acharya, Nisha R. .
OPHTHALMOLOGY, 2007, 114 (02) :246-252
[2]  
Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
[3]  
Brown G C, 2001, Trans Am Ophthalmol Soc, V99, P199
[4]   A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration [J].
Brown G.C. ;
Brown M.M. ;
Lieske H.B. ;
Lieske P.A. ;
Brown K.S. .
International Journal of Retina and Vitreous, 1 (1)
[5]   Cataract Surgery Cost Utility Revisited in 2012 A New Economic Paradigm [J].
Brown, Gary C. ;
Brown, Melissa M. ;
Menezes, Alicia ;
Busbee, Brandon G. ;
Lieske, Heidi B. ;
Lieske, Philip A. .
OPHTHALMOLOGY, 2013, 120 (12) :2367-2376
[6]  
Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
[7]   Patient perceptions of quality-of-life associated with bilateral visual loss [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Brown, HC .
INTERNATIONAL OPHTHALMOLOGY, 1998, 22 (05) :307-312
[8]   Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Brown, H ;
Tasman, W .
OPHTHALMOLOGY, 2000, 107 (07) :1374-1380
[9]  
Brown GC, 2011, EVID BASED OPHTHALMO, V12, P52
[10]  
Brown GC, 2000, CAN J OPHTHALMOL, V35, P27